(0.16%) 5 477.90 points
(0.04%) 39 128 points
(0.49%) 17 805 points
(0.06%) $80.88
(-5.04%) $2.62
(-0.90%) $2 309.80
(-0.36%) $28.77
(2.90%) $1 015.00
(0.35%) $0.936
(0.62%) $10.67
(0.52%) $0.792
(0.90%) $88.28
0.16% $ 12.50
Live Chart Being Loaded With Signals
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors...
Stats | |
---|---|
Volumen de hoy | 3.29M |
Volumen promedio | 3.85M |
Capitalización de mercado | 1.33B |
EPS | $-0.230 ( Q3 | 2023-11-13 ) |
Próxima fecha de ganancias | ( $0 ) 2024-08-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
11.36 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.322 (2.58%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-26 | Goodman Jonathan R. | Sell | 41 872 | Common Stock |
2023-12-27 | Goodman Jonathan R. | Sell | 35 872 | Stock Option (Right to Buy) |
2023-12-27 | Goodman Jonathan R. | Sell | 25 000 | Stock Option (Right to Buy) |
2023-12-27 | Goodman Jonathan R. | Sell | 25 614 | Stock Option (Right to Buy) |
2023-12-27 | Goodman Jonathan R. | Sell | 44 749 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-79.61 |
Last 96 transactions |
Buy: 3 517 450 | Sell: 10 366 533 |
Volumen Correlación
POINT Biopharma Global Correlación
10 Correlaciones Más Positivas | |
---|---|
LVOX | 0.847 |
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
POINT Biopharma Global Correlación - Moneda/Commodity
POINT Biopharma Global Finanzas
Annual | 2022 |
Ingresos: | $226.58M |
Beneficio Bruto: | $226.58M (100.00 %) |
EPS: | $1.040 |
FY | 2022 |
Ingresos: | $226.58M |
Beneficio Bruto: | $226.58M (100.00 %) |
EPS: | $1.040 |
FY | 2021 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-1.181 |
FY | 2020 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-0.00801 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
POINT Biopharma Global
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico